{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T19:13:24Z","timestamp":1789154004620,"version":"build-2803163510"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"33","license":[{"start":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T00:00:00Z","timestamp":1755216000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,8,15]]},"abstract":"<jats:sec>\n                    <jats:title>Rationale:<\/jats:title>\n                    <jats:p>ROS1 rearrangement a distinct molecular subtype of non-small cell lung cancer that is amenable to targeted therapeutic interventions. Despite the availability of effective targeted therapies, the development of acquired resistance to later-line inhibitors, particularly lorlatinib, remains an inevitable, and clinically significant challenge. The emergence of the ROS1 L2086F mutation as a mechanism of lorlatinib resistance further complicates treatment, with limited therapeutic options available post-resistance. This case report evaluates the potential efficacy of cabozantinib, a multi-targeted kinase inhibitor, as a salvage therapy in this specific and challenging clinical context.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patient concerns:<\/jats:title>\n                    <jats:p>A 63-year-old, nonsmoking female presented with cough and expectoration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Diagnoses:<\/jats:title>\n                    <jats:p>The patient was diagnosed with left lower lobe lung adenocarcinoma (cT2N2M1, stage IV), characterized by a CD74-ROS1 fusion mutation. Following disease progression on lorlatinib, next-generation sequencing analysis of pleural effusion identified an acquired ROS1 L2086F resistance mutation, accompanied by a concurrent mTOR mutation and FGFR3 gene amplification.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions:<\/jats:title>\n                    <jats:p>The patient underwent sequential targeted therapy with first-line crizotinib, second-line lorlatinib, and third-line cabozantinib.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcomes:<\/jats:title>\n                    <jats:p>The patient demonstrated a progression-free survival (PFS) of 47 months with first-line crizotinib (PFS1) and 11 months with second-line lorlatinib (PFS2). Upon detection of the L2086F mutation, third-line cabozantinib achieved a clinically significant PFS of 12 months (PFS3), accompanied by disease stabilization and symptomatic relief. The overall survival from initial diagnosis was 73 months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Lessons:<\/jats:title>\n                    <jats:p>This case highlights the clinical efficacy of cabozantinib in overcoming lorlatinib resistance mediated by the ROS1 L2086F mutation, resulting in durable clinical benefits surpassing those of conventional chemotherapy. These findings emphasize the critical role of repeated, comprehensive genomic profiling in managing refractory ROS1-positive non-small cell lung cancer and establish cabozantinib as a viable therapeutic option in this specific resistance context.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000043751","type":"journal-article","created":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T19:01:59Z","timestamp":1755543719000},"page":"e43751","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Cabozantinib overcomes ROS1 L2086F NSCLC resistance to lorlatinib: A case report"],"prefix":"10.1097","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-4429-9299","authenticated-orcid":false,"given":"Xunqi","family":"Liu","sequence":"first","affiliation":[{"name":"The Third People\u2019s Hospital of Shenzhen, Second Affiliated Hospital of Southern University of Science and Technology, Shenzhen City, Guangdong Province, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiong","family":"Chen","sequence":"additional","affiliation":[{"name":"The Third People\u2019s Hospital of Shenzhen, Second Affiliated Hospital of Southern University of Science and Technology, Shenzhen City, Guangdong Province, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Shao","sequence":"additional","affiliation":[{"name":"The Third People\u2019s Hospital of Shenzhen, Second Affiliated Hospital of Southern University of Science and Technology, Shenzhen City, Guangdong Province, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pu","family":"Luo","sequence":"additional","affiliation":[{"name":"The Third People\u2019s Hospital of Shenzhen, Second Affiliated Hospital of Southern University of Science and Technology, Shenzhen City, Guangdong Province, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiang Hong","family":"An","sequence":"additional","affiliation":[{"name":"The Third People\u2019s Hospital of Shenzhen, Second Affiliated Hospital of Southern University of Science and Technology, Shenzhen City, Guangdong Province, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260911","doi-asserted-by":"crossref","first-page":"249","DOI":"10.6004\/jnccn.2204.0023","article-title":"Non-small cell lung cancer, version 4.2024, NCCN clinical practice guidelines in oncology.","volume":"22","author":"Riely","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"key":"R2-20260911","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1016\/S1470-2045(19)30655-2","article-title":"Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1\u20132 trial.","volume":"20","author":"Shaw","year":"2019","journal-title":"Lancet Oncol"},{"key":"R3-20260911","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/s41571-020-0408-9","article-title":"ROS1-dependent cancers - biology, diagnostics and therapeutics.","volume":"18","author":"Drilon","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"R4-20260911","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41698-024-00663-1","article-title":"TKI type switching overcomes ROS1 L2086F in ROS1 fusion-positive cancers.","volume":"8","author":"Thawani","year":"2024","journal-title":"NPJ Precis Oncol"},{"key":"R5-20260911","doi-asserted-by":"crossref","first-page":"371","DOI":"10.3390\/ph13110371","article-title":"Later-line treatment with lorlatinib in ALK- and ROS1-rearrangement-positive NSCLC: a retrospective, multicenter analysis.","volume":"13","author":"Hochmair","year":"2020","journal-title":"Pharmaceuticals (Basel)"},{"key":"R6-20260911","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1158\/1078-0432.CCR-21-0032","article-title":"Spectrum of mechanisms of resistance to crizotinib and lorlatinib in ROS1 fusion\u2013positive lung cancer.","volume":"27","author":"Lin","year":"2021","journal-title":"Clin Cancer Res"},{"key":"R7-20260911","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1200\/JCO.22.02546","article-title":"Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy.","volume":"41","author":"Hanna","year":"2023","journal-title":"J Clin Oncol"},{"key":"R8-20260911","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/j.jtho.2018.05.026","article-title":"Characteristics and outcome of ROS1-positive non-small cell lung cancer patients in routine clinical practice.","volume":"13","author":"Park","year":"2018","journal-title":"J Thorac Oncol"},{"key":"R9-20260911","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/j.jtho.2016.03.022","article-title":"Efficacy of pemetrexed-based chemotherapy in patients with ROS1 fusion\u2013positive lung adenocarcinoma compared with in patients harboring other driver mutations in East Asian populations.","volume":"11","author":"Chen","year":"2016","journal-title":"J Thorac Oncol"},{"key":"R10-20260911","first-page":"81","article-title":"TKI-resistant ALK-rearranged lung adenocarcinoma with secondary CTNNB1 p.S45V and tertiary ALK p.I1171N mutations.","volume":"10","author":"Ouseph","year":"2019","journal-title":"Lung Cancer (Auckl)"},{"key":"R11-20260911","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1186\/s13046-021-02080-9","article-title":"CIRP promotes the progression of non-small cell lung cancer through activation of Wnt\/\u03b2-catenin signaling via CTNNB1.","volume":"40","author":"Liao","year":"2021","journal-title":"J Exp Clin Cancer Res"},{"key":"R12-20260911","doi-asserted-by":"crossref","first-page":"32","DOI":"10.21873\/cdp.10409","article-title":"Tumor \u03b2-catenin expression associated with poor prognosis to anti-PD-1 antibody monotherapy in non-small cell lung cancer.","volume":"5","author":"Muto","year":"2025","journal-title":"Cancer Diagn Progn"},{"key":"R13-20260911","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1200\/JCO.23.00580","article-title":"Genomic and immunophenotypic landscape of acquired resistance to PD-(L)1 blockade in non-small-cell lung cancer.","volume":"42","author":"Ricciuti","year":"2024","journal-title":"J Clin Oncol"},{"key":"R14-20260911","doi-asserted-by":"crossref","first-page":"1516583","DOI":"10.3389\/fphar.2025.1516583","article-title":"Targeting the PI3K\/AKT\/mTOR pathway in lung cancer: mechanisms and therapeutic targeting.","volume":"16","author":"Qiang","year":"2025","journal-title":"Front Pharmacol"},{"key":"R15-20260911","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.semcancer.2021.06.019","article-title":"Attacking the PI3K\/Akt\/mTOR signaling pathway for targeted therapeutic treatment in human cancer.","volume":"85","author":"Yu","year":"2022","journal-title":"Semin Cancer Biol"},{"key":"R16-20260911","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s12943-023-01827-6","article-title":"PI3K\/AKT\/mTOR signaling transduction pathway and targeted therapies in cancer.","volume":"22","author":"Glaviano","year":"2023","journal-title":"Mol Cancer"},{"key":"R17-20260911","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s12943-024-02019-6","article-title":"CircTRIM1 encodes TRIM1-269aa to promote chemoresistance and metastasis of TNBC via enhancing CaM-dependent MARCKS translocation and PI3K\/AKT\/mTOR activation.","volume":"23","author":"Li","year":"2024","journal-title":"Mol Cancer"},{"key":"R18-20260911","doi-asserted-by":"crossref","first-page":"217124","DOI":"10.1016\/j.canlet.2024.217124","article-title":"Triple combination therapy comprising osimertinib, an AXL inhibitor, and an FGFR inhibitor improves the efficacy of EGFR-mutated non-small cell lung cancer.","volume":"598","author":"Nakamura","year":"2024","journal-title":"Cancer Lett"},{"key":"R19-20260911","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.jtho.2024.11.027","article-title":"Receptor tyrosine kinase fusion-mediated resistance to EGFR TKI in EGFR-mutant NSCLC: a multi-center analysis and literature review.","volume":"20","author":"Xia","year":"2025","journal-title":"J Thorac Oncol"},{"key":"R20-20260911","doi-asserted-by":"crossref","first-page":"3293","DOI":"10.3390\/cancers12113293","article-title":"Focus on ROS1-positive non-small cell lung cancer (NSCLC): crizotinib, resistance mechanisms and the newer generation of targeted therapies.","volume":"12","author":"D\u2019Angelo","year":"2020","journal-title":"Cancers (Basel)"},{"key":"R21-20260911","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.jtho.2023.12.008","article-title":"Comprehensive review of ROS1 tyrosine kinase inhibitors-classified by structural designs and mutation spectrum (solvent front mutation [G2032R] and central \u03b2-sheet 6 [C\u03b26] mutation [L2086F]).","volume":"19","author":"Ou","year":"2024","journal-title":"J Thorac Oncol"},{"key":"R22-20260911","first-page":"100673","article-title":"L2086F mutant ROS1-rearranged NSCLC resistant to repotrectinib responds to cabozantinib: a case report.","volume":"5","author":"Weber","year":"2024","journal-title":"JTO Clin Res Rep"},{"key":"R23-20260911","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41698-023-00381-0","article-title":"Exceptional response to lorlatinib and cabozantinib in ROS1-rearranged NSCLC with acquired F2004V and L2086F resistance.","volume":"7","author":"Sakamoto","year":"2023","journal-title":"NPJ Precis Oncol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000043751","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T19:02:20Z","timestamp":1789153340000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000043751"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,15]]},"references-count":23,"journal-issue":{"issue":"33","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000043751","relation":{},"ISSN":["1536-5964","0025-7974"],"issn-type":[{"value":"1536-5964","type":"electronic"},{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8,15]]},"assertion":[{"value":"2025-02-17","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-17","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}